Dosimetric predictors of acute bowel toxicity after Stereotactic Body Radiotherapy (SBRT) in the definitive treatment of localized prostate cancer

References

• Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–436.
   PubMed Web of Science ®Google Scholar
• Hung AY, Levy L, Kuban DA. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis. Cancer J Sudbury Mass. 2002;8(6):440–444.
   PubMed Web of Science ®Google Scholar
• Royce TJ, Mavroidis P, Wang K, et al. Tumor control probability modeling and systematic review of the literature of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2021; 110(1):227–236.
   PubMed Web of Science ®Google Scholar
• Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet Lond Engl. 2019; 394(10196):385–395.
   PubMed Web of Science ®Google Scholar
• Fransson P, Nilsson P, Gunnlaugsson A, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol. 2021; 22(2):235–245.
   PubMed Web of Science ®Google Scholar
• Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019; 20(11):1531–1543.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Prostate Cancer [Internet]. Version 4; 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
   Google Scholar
• Alongi F, Cozzi L, Arcangeli S, et al. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol. 2013; 8(1):171.
   PubMed Web of Science ®Google Scholar
• Fuller DB, Naitoh J, Lee C, et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys. 2008; 70(5):1588–1597.
   PubMed Web of Science ®Google Scholar
• Leeman JE, Cagney DN, Mak RH, et al. Magnetic resonance–guided prostate stereotactic body radiation therapy with daily online plan adaptation: results of a prospective phase 1 trial and supplemental cohort. Adv Radiat Oncol. 2022;7(5):100934.
   PubMedGoogle Scholar
• Alayed Y, Quon H, Cheung P, et al. Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: a quality of life analysis of two prospective clinical trials. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2019; 140:105–109.
   PubMed Web of Science ®Google Scholar
• Fuller DB, Crabtree T, Kane BL, et al. High dose “HDR-Like” prostate SBRT: PSA 10-year results from a mature, multi-institutional clinical trial. Front Oncol. 2022;12:935310.
   PubMed Web of Science ®Google Scholar
• Paydar I, Cyr RA, Yung TM, et al. Proctitis 1 week after stereotactic body radiation therapy for prostate cancer: implications for clinical trial design. Front Oncol. 2016;6:167.
   PubMed Web of Science ®Google Scholar
• Bhattasali O, Chen LN, Woo J, et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol Lond Engl. 2014;9:52.
   PubMed Web of Science ®Google Scholar
• Chen LN, Suy S, Uhm S, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown university experience. Radiat Oncol Lond Engl. 2013;8:58.
   PubMed Web of Science ®Google Scholar
• Hall WA, Paulson E, Davis BJ, et al. NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer. Int J Radiat Oncol Biol Phys. 2021;109(1):174–185.
   PubMed Web of Science ®Google Scholar
• Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl. 1985;8: s 13–19.
   PubMedGoogle Scholar
• Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys. 1989; 16(6):1623–1630.
   PubMed Web of Science ®Google Scholar
• Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991; 21(1):123–135.
   PubMed Web of Science ®Google Scholar
• Kutcher GJ, Burman C, Brewster L, et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys. 1991; 21(1):137–146.
   PubMed Web of Science ®Google Scholar
• Vernia P, Fracasso PL, Casale V, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet Lond Engl. 2000; 356(9237):1232–1235.
   PubMed Web of Science ®Google Scholar
• Kim DWN, Cho LC, Straka C, et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014; 89(3):509–517.
   PubMed Web of Science ®Google Scholar
• Pasalic D, Prajapati S, Ludmir EB, et al. Outcomes and toxicities of proton and photon radiation therapy for testicular seminoma. Int J Part Ther. 2020; 7(2):11–20.
   PubMedGoogle Scholar
• Leufgens F, Gharib A, Schlenter M, et al. Consequential late effects up to >10 years following primary and postoperative radiotherapy for prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2021; 156:188–192.
   PubMed Web of Science ®Google Scholar
• Mariados N, Sylvester J, Shah D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol. 2015;92(5):971–977.
   PubMed Web of Science ®Google Scholar
• Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol. 2017; 97(5):976–985.
   PubMed Web of Science ®Google Scholar
• Fischer-Valuck BW, Chundury A, Gay H, et al. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. Pract Radiat Oncol. 2017; 7(3):195–202.
   PubMed Web of Science ®Google Scholar
• Kataria S, Hong RL, McRae D, et al. The rectal dosimetric effects of perirectal hydrogel spacers in men undergoing prostate stereotactic body radiation therapy (SBRT). Int J Radiat Oncol. 2017; 99(2, Supplement):E676.
   Web of Science ®Google Scholar
• Payne HA, Pinkawa M, Peedell C, et al. SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: a systematic review. Medicine (Baltimore). 2021; 100(49):e28111.
   PubMed Web of Science ®Google Scholar